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Brain tumors are the most common solid pediatric malignancy. For high-grade, recurrent, or
refractory pediatric brain tumors, radiation therapy (XRT) is an integral treatment modality.
In the era of personalized cancer therapy, molecularly targeted agents have been designed
to inhibit pathways critical to tumorigenesis. Our evolving knowledge of genetic aberrations
in pediatric gliomas is being exploited with the use of specific targeted inhibitors. These
agents are additionally being combined with XRT to increase the efficacy and duration of
local control. In this review, we discuss novel agents targeting three different pathways
in gliomas, and their potential combination with XRT. BRAF is a serine/threonine kinase
in the RAS/RAF/MAPK kinase pathway, which is integral to cellular division, survival, and
metabolism. Two-thirds of pilocytic astrocytomas, a low-grade pediatric glioma, contain a
translocation within the BRAF gene called KIAA1549:BRAF that causes an overactivation
of the MEK/MAPK signaling cascade. In vitro and in vivo data support the use of MEK
or mammalian target of rapamycin (mTOR) inhibitors in low-grade gliomas expressing this
translocation. Additionally, 15–20% of high-grade pediatric gliomas express BRAF V600E,
an activating mutation of the BRAF gene. Pre-clinical in vivo and in vitro data in BRAFV600E
gliomas demonstrate dramatic cooperation between XRT and small molecule inhibitors of
BRAF V600E. Another major signaling cascade that plays a role in pediatric glioma patho-
genesis is the PI3-kinase (PI3K)/mTOR pathway, known to be upregulated in the majority
of high- and low-grade pediatric gliomas. Dual PI3K/mTOR inhibitors are in clinical trials for
adult high-grade gliomas and are poised to enter studies of pediatric tumors. Finally, many
brain tumors express potent stimulators of angiogenesis that render them refractory to
treatment. An analog of thalidomide, CC-5103 increases the secretion of critical cytokines
of the tumor microenvironment, including IL-2, IFN-γ, TNF-α, and IL-10, and is currently
being evaluated in clinical trials for the treatment of recurrent or refractory pediatric central
nervous system tumors. In summary, several targeted inhibitors with radiation are cur-
rently under investigation in both translational bench research and early clinical trials. This
review article summarizes the molecular rationale for, and the pre-clinical data supporting
the combinations of these targeted agents with other anti-cancer agents and XRT in pedi-
atric gliomas. In many cases, parallels are drawn to molecular mechanisms and targeted
inhibitors of adult gliomas. We additionally discuss the potential mechanisms underlying
the efficacy of these agents.
Keywords: pediatric gliomas, low-grade glioma, BRAFV600E, PI3K/AKT/mTOR, angiogenesis inhibitors,
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INTRODUCTION
Recent, exciting advances in pediatric oncology are revealing the
molecular underpinnings of pediatric brain tumors (Nakamura
et al., 2007), as well as important genetic differences between
pediatric and adult central nervous system (CNS) malignancies
(Gilheeney and Kieran, 2012). As brain tumors remain the most
common solid malignancy of childhood, numerous molecularly
targeted strategies are under investigation to decrease recurrence,
prolong survival, and minimize toxicity in children treated with
brain tumors. This article summarizes three of the major pathways
targeted by novel inhibitors in the clinic, with a particular focus
on low-grade gliomas in children.
BRAF
BRAF is a cytosolic serine-threonine kinase and, together with A-
Raf and C-Raf, is a member of the RAF family of kinases. BRAF
is activated by receptor tyrosine kinases in the cell membrane and
is a major regulator of the MEK/MAPK cascade, which regulates
cell differentiation, invasion, dedifferentiation, and proliferation
(McCubrey et al., 2012).
Molecular profiling of tissues from different human cancers
has shown that mutations of the BRAF gene at locus 1799 (amino
acid 600) are the second most common mutations in human can-
cers, found in 40% of papillary thyroid carcinomas and 40–60%
of melanomas (McCubrey et al., 2012). In this mutation, a valine
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in the activation segment of the enzyme is replaced with a nega-
tively charged glutamic acid, mimicking a phosphorylation of the
active site, and interacting with the P loop. The mutation causes
constitutive activation of the BRAF kinase as well as downstream
players in the signaling cascade (Figure 1). The prevalence of this
mutation has led to the development of specific inhibitors against
BRAF V600E, including vemurafenib (PLX4032, pre-clinical ana-
log PLX4720) (Chapman et al., 2011) and dabrafenib, both of
which have shown remarkable efficacy in BRAF V600E-mutated
metastatic melanoma in Phase III clinical trials (Hauschild et al.,
2012), and are discussed further below.
The activating BRAF V600E is found in 10–25% of grade 2–
4 pediatric gliomas (Schiffman et al., 2010). In one study of 27
pediatric grade I and II pediatric brain tumors, the frequency
of BRAF V600E mutation was queried using an oligonucleotide
microarray, and 14 of 31 tumors (40%) were found to encode the
BRAF V600E mutation (Dougherty et al., 2010). Anatomically,
BRAF V600E mutations have been associated with extracerebellar
pilocytic astrocytomas (instead of infratentorial ones) (Schindler
et al., 2011). In some cases (five of seven in this series), these
oncogenic BRAF mutations were associated with homozygous
deletions of CDKN2A (Schiffman et al., 2010). There continues
to remain controversy about the prognostic significance of the
BRAF V600E mutation in pediatric gliomas. In a study of 198 pedi-
atric low-grade gliomas, a BRAF V600E mutation was associated
with poorer outcomes and decreased progression-free survival in
patients, though the poorest survival was predicted by a midline
anatomic location (Horbinski et al., 2012).
Another genetic aberration in BRAF in addition to BRAF
V600E point mutations that leads to increased kinase activity in
low- and high-grade pediatric brain tumors is a fusion protein of
KIAA1549:BRAF that is found in the majority of pilocytic astro-
cytomas. The significance of this fusion is not well understood
(Schiffman et al., 2010; Ida et al., 2012; Lin et al., 2012). Sev-
eral studies suggest that, unlike the BRAF V600E mutation, the
KIAA1549:BRAF fusion is associated with an infratentorial loca-
tion for pilocytic astrocytomas (Horbinski et al., 2010; Lin et al.,
2012). One recent study of 51 pilocytic astrocytomas suggests that
the presence of a KIAA1549:BRAF fusion should be associated
with a pilocytic classification, while a BRAF V600E mutation is
more prevalent in non-pilocytic gliomas (Tian et al., 2011). There
is some evidence that in pilocytic astrocytomas, the fusion pro-
tein is associated with a favorable outcome (Hawkins et al., 2011),
while another series did not find any correlation with the BRAF
fusion protein and disease progression (Lin et al., 2012).
The prevalence of oncogenic BRAF V600E mutations in sev-
eral solid tumors has led to the development of anti-cancer
agents that specifically inhibit BRAF V600E. PLX4032 or vemu-
rafenib (F. Hoffman-La Roche AG) was the first inhibitor devel-
oped to demonstrate preferential activity against the BRAF V600E
mutant protein versus the wild-type protein. In the BRIM3 trial,
vemurafenib has shown remarkable activity against BRAF V600E
metastatic melanoma, with 80% of patients showing either par-
tial or complete remission, 74% reduction in disease progression
or death, and a survival advantage over patients treated with
dacarbazine alone, the standard of care (Chapman et al., 2011).
Vemurafenib was subsequently FDA-approved for the treatment
of BRAF V600E-mutated metastatic melanoma. Dabrafenib has
also prolonged progression-free survival and overall survival when
compared to dacarbazine in patients with BRAF V600E mutated
melanoma in the BREAK3 trial (Hauschild et al., 2012). There
is clinical evidence that dabrafenib also crosses the blood brain
FIGURE 1 | Novel targeted agents and the pathways inhibited in solid tumors.
Frontiers in Oncology | Radiation Oncology May 2013 | Volume 3 | Article 110 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dasgupta and Haas-Kogan Targeted agents and radiation in pediatric gliomas
barrier, which supports its use in neuro-oncology (Long et al.,
2012). Both dabrafenib and vemurafenib are remarkably well tol-
erated, with fatigue and photosensitivity being the major side
effects. A small proportion of metastatic melanoma patients has
developed a secondary skin cancer called keratoacanthoma while
receiving BRAF V600E inhibitors, but these are considered to
be treatable lesions with local therapy (excision or radiation),
and some lesions have even disappeared with discontinuation of
therapy (Falchook et al., 2012).
Excitingly, pre-clinical data in intracranial xenografts of pedi-
atric gliomas suggest a role for BRAF V600E inhibitors in the
treatment of pediatric gliomas. Recently published in vivo murine
data suggest that BRAF inhibitors may be effective in high-
grade gliomas expressing the BRAF V600E mutation (Nicolaides
et al., 2011). This efficacy of PLX4720 (the pre-clinical analog
of vemurafenib) has also been seen in a xenograft flank tumor
mouse model of BRAF V600E-mutated pediatric pilocytic astro-
cytoma (our unpublished results). Furthermore, in an intracranial
xenograft model of BRAF V600E-mutated glioma, mice were
randomized to receive vector alone, BRAF inhibitor (PLX4720)
alone, radiation alone, or a combination of both radiation and
BRAF inhibitor. The data showed that combination treatment
with radiation and BRAF inhibitor PLX4720 led to a statistically
significant survival advantage in these mice, when compared to
treatment with vehicle (p< 0.0001), PLX4720 (p= 0.0098), or
radiation (p= 0.0059). Combination treatment with PLX4720
and radiation led to a lower tumor proliferation index (Ki67).
There was equivalent survival in the combination arms regardless
of how radiation was sequenced with the BRAF inhibitor, either
concurrently or sequentially (Dasgupta et al., 2012).
These translational studies will inform the next generation
of clinical trials of BRAF V600E inhibitors and radiation in
patients with BRAF V600E-mutated brain tumors and metastases.
At least one of these studies is underway under the umbrella
of the Pacific Pediatric Neuro-Oncology Consortium (PNOC,
http://www.pnoc.us). This Phase I study will establish the safety
and pharmacokinetic characteristics of vemurafenib in children
with recurrent or refractory gliomas containing the BRAF V600E
mutation. Using the recommended Phase II dose, this trial will
proceed to a Phase II study in a pre-surgical cohort of 10 patients
requiring debulking surgery at the time of recurrence. These
patients will receive neo-adjuvant vemurafenib, allowing measure-
ments of intra-tumoral drug concentrations and target inhibition.
An expansion cohort will then be enrolled to estimate efficacy.
Children will also be carefully followed for the development of
dermal lesions that may be comparable to the keratoacanthomas
seen in adults. This trial will start accruing in 2013. If the dose
limiting toxicities of vemurafenib in this trial are not prohibitive
to its administration in children, then a possible next step will be to
provide combination treatment of vemurafenib with concurrent
external beam radiation in children with BRAF V600E-mutated
high-grade gliomas, or recurrent BRAF V600E-mutated low-grade
gliomas.
Resistance to BRAF V600E inhibitors has manifested in the
clinic. In BRAF V600E-mutated melanomas, after an initial robust
response, there is disease progression within a median of 5–
7 months. It is hypothesized that signaling through redundant
pathways involving the PI3-kinase (PI3K)/mammalian target of
rapamycin (mTOR),VEGF, RAS/RAF/MEK/ERK, and EGFR path-
ways contributes to such drug resistance (Jang and Atkins, 2013).
For example, colon cancers with BRAF V600E mutations do not
respond to vemurafenib due to feedback activation of EGFR.
Therefore, in pre-clinical studies, vemurafenib is strongly synergis-
tic with EFGR inhibitors like cetuximab for colon cancers express-
ing BRAF V600E mutations (Prahallad et al., 2012). Whether
resistance to BRAF V600E inhibitors also arises in gliomas, where
EGFR and PI3K/mTOR pathways are often over-activated, remains
to be seen in neuro-oncology patients treated with BRAF V600E
inhibitors.
Finally, pediatric oncologists should be cautioned that, with
the exception of a single case report (Rush et al., 2013), there
is little experience using dabrafenib or vemurafenib in children,
and the efficacy of BRAF V600E inhibitors against tumors with
the KIAA1549:BRAF molecular fusion is unknown. Additionally,
a recent abstract suggests that in glioma cell lines engineered to
express the KIAA1549:BRAF fusion, there is resistance to therapy
with BRAF V600E inhibitors, and in fact, the paradoxical growth
activation (previously only seen in wild-type BRAF cells treated
with BRAF V600E inhibitors) is observed (Lang et al., 2012).
MAMMALIAN TARGET OF RAPAMYCIN
Mammalian target of rapamycin is a serine-threonine kinase in
the phosphatidylinositol kinase (PI3K) family that signals down-
stream of metabolite-sensing pathways, and regulates cellular pro-
liferation, apoptosis, and autophagy (McCubrey et al., 2012). The
primary signals activating mTOR are derived from insulin growth
factor receptor (IGFR) and the amino acid transporter pathway.
Therefore, activation of the mTOR pathway is a reflection of the
nutritional status and extracellular stresses in the cellular microen-
vironment. Many components of the mTORC1 and mTORC2
complexes, in addition to their downstream targets, have been
associated with human cancers (Figure 1).
Mammalian target of rapamycin itself forms the catalytic sub-
unit of two protein complexes, mTORC1 and mTORC2. mTORC1
is comprised of several proteins including mTOR, RAPTOR, DEP-
TOR, PRAS40, and mLST8/GL. This complex is activated by extra-
cellular amino acids that enable mTORC1 to interact with RHEB,
the convergence point of amino acid metabolism and insulin sig-
naling. RAPTOR inhibits the kinase activity of mTOR: in high
nutrient states, conformational changes occur to expose the mTOR
active site to solution. mTOR is then activated as a kinase and can
phosphorylate p70-S6 kinase, which then phosphorylates down-
stream targets like S6 (to form phosphorylated S6, or phospho-S6)
and the eukaryotic initiation factor 4E (4EBP1, to form phospho-
4EBP1) that increase protein translation and also activate mTOR
activity by a positive feedback loop. PRAS40 is a negative regulator
of mTORC1, but phosphorylation of PRAS40 by Akt can prevent
this inhibition and additionally activate the mTORC1 complex
(Manning and Cantley, 2007; Wang et al., 2007).
The mTORC2 complex also responds to nutrient levels and
redox states, but with the cellular cytoskeleton as its target. mTOR,
RICTOR (rapamycin insensitive companion of mTOR), GβL,
and mSIN (mammalian stress-activated protein 1) comprise the
mTORC2 complex. A critical function of mTORC2 is activation
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of Akt (Protein kinase B1) via PDK1 stimulation. Given the
role of Akt in diverse cellular processes like glucose metabolism,
apoptosis, cell cycle regulation, and transcription, it is not sur-
prising that the mTORC2 complex is an important therapeutic
target in cancer therapy (Populo et al., 2012). In an interest-
ing study of regulation of neural stem cell growth Kaul et al.
(2012) demonstrate that divergent pathways converge at mTOR
to activate growth in gliomas with different driver mutations. In
sporadic low-grade gliomas driven by KIAA1549:BRAF and famil-
ial low-grade gliomas associated with protein neurofibromin 1
(NF1), mTOR represents a central growth control target. How-
ever, the two mechanisms of mTOR activation are distinct in
that KIAA1549:BRAF activates mTOR through MEK-dependent
tuberin inactivation whereas NF1 loss leads to TORC2-dependent
AKT activation. These distinct mechanisms of mTOR activation
notwithstanding, mTOR represents a promising therapeutic target
in sporadic and NF1 associated low-grade gliomas.
The PI3K/Akt/mTOR axis is also activated in a substantial
percentage of pediatric brain tumors. In newly diagnosed pedi-
atric gliomas, 80% of high-grade gliomas and 50% of low-
grade gliomas showed enhanced expression of phospho-S6 and
phospho-4EBP1, the major downstream targets of mTORC1.
Expression of phospho-S6 and/or phospho-4EBP1 has also been
associated with a statistically significant decrease in progression-
free survival (PFS), regardless of tumor grade (Populo et al., 2012).
In low-grade adult brain tumors, activation of the PI3K/mTOR
pathway portends shorter overall survival. In a study of 45 newly
diagnosed pediatric brain tumors, there was a strong correlation
between phospho-S6 expression and decreased survival. There
was also a trend toward decreased survival in patients whose
tumors expressed phospho-PRAS40. Phospho-S6 expression cor-
related with PTEN methylation in these tumors as well (McBride
et al., 2010). Also, in a molecular analysis study of 92 pilo-
cytic astrocytomas including 43 conventional pilocytic astrocy-
tomas, 25 clinically aggressive/recurrent pilocytic astrocytomas,
and 25 anaplastic pilocytic astrocytomas, an increase in cyto-
plasmic phosphorylated-Akt (phospho-Akt) and phospho-S6 was
associated with anaplastic histology (a more aggressive pheno-
type) and poorer outcomes in pilocytic astrocytomas (Rodriguez
et al., 2011). mTOR activation has also been associated with a
particular subset of pilocytic astrocytomas called the “low-grade
astrocytoma subtype intermediate” (LGSI), found in patients with
syndrome neurofibromatosis 1 (NF-1) (Jentoft et al., 2010).
Given the up-regulation of mTOR/PI3K pathway in numer-
ous human cancers, several inhibitors of the mTOR pathway have
been developed (Fasolo and Sessa, 2012). The first inhibitor of
mTOR was rapamycin or sirolimus, initially developed as an anti-
fungal and then an immunosuppressant for transplant patients.
Rapamycin forms a complex with FK506 that in turn interacts
with the C-terminus of mTOR and inhibits the mTORC1 com-
plex. Two derivatives of rapamycin, temsirolimus (CCI-779) and
everolimus (RAD001, Affinitor), are currently in the cancer clinic.
Temsirolimus was FDA-approved to treat mantle cell lymphoma
(Samad and Younes, 2010), and everolimus was initially approved
to treat renal carcinoma in 2009 (Motzer et al., 2008), as well
as subependymal giant cell astrocytomas (SEGAs) in patients
with tuberous sclerosis (TSC; see below) (Krueger et al., 2010).
Subsequently, everolimus been shown to increase PFS when used
in combination with exemestane in patients with advanced breast
cancer. Several ATP-competitive mTOR inhibitors are also being
tested in the clinic. PP242 is an ATP-competitive inhibitor iden-
tified by kinome profiling and has shown activity against both
mTORC1 and mTORC2 (Hoang et al., 2012). Other active site
inhibitors of mTORC kinase are at different stages of develop-
ment including Torin-1 and WYE-354 (in pre-clinical studies) and
AZD8055, AZD2014, OSI-027, and MLN0128 (in clinical trials)
(Laplante and Sabatini, 2012).
Many early mTOR inhibitors were found to have activity against
both PI3K and mTOR because of the sequence and structural
homology shared by PI3K and mTOR in the ATP-binding cleft.
It soon became apparent that such dual inhibitors had “classical
hinge kinase binders” as their scaffold, as in XL765 (SAR245409)
(Prasad et al., 2011), NVP-BEZ235 (Doghman and Lalli, 2012),
GNE-317 (Salphati et al., 2012), OSI-027 (Bhagwat et al., 2011),
and SF1126 (Mahadevan et al., 2012). These dual inhibitors can
potently inhibit multiple downstream pathways and induce apop-
tosis in a number of cancers from different tumor tissues. The
majority of these dual inhibitors are lipophilic, necessitating the
development of a second generation of these compounds to over-
come solubility issues by linking rapamycin to a PI3K inhibitor
with a soluble linker. Many of these compounds are currently
in clinical trials for various solid tumors (Molckovsky and Siu,
2008).
Can inhibitors of the mTOR/PI3K axis be used to treat gliomas?
As outlined above, the PI3K/mTOR pathway is activated in over
half of low-grade gliomas. Pre-clinical data from our laboratory
strongly support a role for PI3K/mTOR inhibitors in adult and
pediatric low-grade gliomas. Recently published studies show that
XL765, a dual PI3K/mTOR inhibitor, has potent activity in an
intracranial xenograft mouse model of high-grade glioma. Fur-
thermore, XL765 also shows synergistic activity with temozolo-
mide in high-grade glioma xenografts (Prasad et al., 2011) and is
currently under evaluation in Phase I clinical trials for adult brain
tumors, in combination with temozolomide (Nghiemphu et al.,
2010).
Additionally, pre-clinical data from our laboratory were one
of the first to demonstrate a correlation between PTEN expres-
sion, Akt activity, and glioma histology in adults. More aggressive
gliomas like glioblastomas had decreased levels of PTEN, which
correlated with higher levels of Akt activity. In adult low-grade
gliomas, there was also decreased PTEN expression, without dis-
cernible PTEN losses or mutation, and this decreased PTEN
expression was associated with increased activity of the Akt path-
way (Ermoian et al., 2002). Interestingly, another brain tumor that
also demonstrates this molecular signature of mTOR activation is
TSC-associated SEGA. In a landmark series of 28 patients aged
3 years or greater with SEGAs, tumors showed an unprecedented
response in 75% of patients treated with everolimus. The duration
of response was over 3 months, no other therapy was required,
and patients experienced symptomatic relief of their seizure fre-
quency. The most common adverse effects were stomatitis, upper
respiratory tract infections, sinusitis, otitis media, and pyrexia.
Grade 3 adverse events were noted in 36% of patients and included
infections, stomatitis, and convulsions (Krueger et al., 2010).
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These data from TSC suggest that low-grade gliomas
with mTOR activation may also benefit from treatment with
everolimus. Therefore, researchers at University of California San
Francisco have started a Phase II trial of everolimus for the treat-
ment of adults with recurrent low-grade gliomas (Haas-Kogan
et al., 2013). Between 2009 and 2012, 36 patients with low-grade
gliomas have been enrolled. Histologies at original diagnosis were
oligodendroglioma (n= 14), astrocytoma (n= 9), and oligoastro-
cytoma (n= 13). However, at time of recurrence (prior to study
enrollment), 9 of the 36 patients had transformed to higher-
grade disease. Prior to treatment with everolimus, 11 patients had
received radiation and 23 had received temozolomide. Currently,
11 patients continue on active therapy with everolimus, 15 have
progressive disease, and the remaining discontinued drug due to
toxicity (n= 2), poor follow-up (n= 1), refusal of further therapy
(n= 4), or unrelated inter-current disease (n= 2). Encouragingly,
15 patients had stable disease for over a year, and four had stable
disease for over 2 years while on treatment, all despite multiple
prior recurrences (Haas-Kogan et al., 2013).
Additionally, our laboratory is currently seeking to exploit
recent findings that suggest crosstalk between the BRAF and
PI3K/mTOR signaling pathways as driving mutations in pedi-
atric gliomas. In a recent study performed on neural stem cells,
cross talk between the KIAA1549:BRAF fusion protein and the
mTOR pathway has been demonstrated. The neural stem cell
proliferation secondary to the BRAF fusion protein is actually
mediated by hyper-activation of the mTOR pathway, suggest-
ing crosstalk between these two critical pathways in pediatric
gliomagenesis (Kaul et al., 2012). Given the prevalence of acti-
vation of the PI3K/mTOR axis and BRAF V600E mutations in
pediatric tumors, we designed a pre-clinical study to determine
whether inhibitors of mTOR and of BRAF V600E cooperate to
enhance cytotoxicity specifically in pediatric low-grade gliomas.
In an in vivo flank model of a pediatric pilocytic astrocytoma,
subcutaneous xenografts of BT40 (which carries a BRAF V600E
mutation) were treated with vehicle, PLX4720, everolimus, or
combination of PLX4720+ everolimus, and the outcome mea-
sures of tumor size and animal survival were followed. In murine
xenografts of a pilocytic astrocytoma with mutated BRAF V600E,
treatment with PLX4720+ everolimus led to a statistically signifi-
cant survival advantage, when compared to treatment with vehicle
alone (p= 0.0002), PLX4720 alone (p= 0.0126), or everolimus
alone (p= 0.0031). Treatment with PLX4720+ everolimus also
led to significantly smaller tumors when compared to treatment
with vehicle alone (p< 0.0001), PLX4720 alone (p< 0.0001), or
everolimus alone (p= 0.0082). This is the first in vivo demon-
stration of combinatorial activity of an mTOR inhibitor with a
BRAF inhibitor in gliomas, and will inform future clinical trials in
pediatric brain tumor patients (Dasgupta et al., 2013).
ANGIOGENESIS
Angiogenesis is a tightly regulated process by which novel vascu-
lature forms in the brain. In brain tumors, this process enables
transformation to a more vascular or angiogenic phenotype.
Gliomas are hyper-vascular tumors, and routinely overexpress
pro-angiogenic factors like VEGF, EGF, PDGF, FGF, SDF-1, Tie2,
and TGF-beta. In fact, the PI3K/Akt pathway, described above,
also increases angiogenesis by up-regulation of VEGF and HIF1α
(Jensen, 1998). In gliomas, there is evidence that p53 mutations
significantly increase the mean vessel density of pilocytic astrocy-
tomas, and affect important regulators of angiogenesis including
thrombospondin-1, serpin E1, and MMP-9 (Gaiser et al., 2009).
Given the utility of bevacizumab (Avastin, an inhibitor of VEGF-
A) in the clinic to treat recurrent gliomas (Sweet et al., 2012),
inhibitors of angiogenesis have become an attractive target in the
neuro-oncology clinic (Butowski, 2011).
Angiogenesis may also correlate with brain tumor progno-
sis. Nearly two decades ago, contrast enhancement in low-grade
gliomas was recognized to portend poor outcomes in patients
(Piepmeier, 1987). The density of blood vessels is a prognostic
indicator for patients with gliomas: higher blood vessel density
correlates with poorer survival (Leon et al., 1996). Some studies
have suggested that low-grade gliomas integrate existing vascula-
ture in the brain, while glioblastomas become hyper-vascular by
angiogenesis (Folkerth, 2000). More recently, an interesting MRI
study performed in 46 adults with low-grade gliomas showed that
both microvascular leakage and contrast enhancement in low-
grade gliomas were associated with the lowest PFS (Piepmeier,
1987; Dhermain et al., 2010).
Pilocytic astrocytomas are particularly vascular tumors, and
therefore there is great interest in targeting angiogenesis in these
low-grade gliomas. Researchers have also examined KIT expres-
sion in 35 pilocytic astrocytomas and 45 other pediatric brain
tumors using immunohistochemistry. They found that 35% of
pilocytic astrocytomas express KIT, as do some of the normal
brain specimens. KIT was also found in the endothelial cells of
pediatric brain tumors, and was more common in pilocytic astro-
cytomas diagnosed at a young age (Puputti et al., 2010). In a study
comparing the vasculature of 59 pilocytic astrocytomas to that
of 62 adult glioblastomas, researchers examined the vessel matu-
rity, vessel turnover, and VEGF expression between the pilocytic
astrocytomas and glioblastomas. They found that pilocytic astro-
cytomas had less turnover of blood vessels, and had larger but
fewer blood vessels than glioblastomas. There was a correlation
between the decreased number of vessels and higher expression of
VEGF-A, suggesting that pilocytic astrocytomas may overexpress
this protein. The authors suggested that VEGF-A might serve as a
druggable target in pilocytic astrocytomas (Sie et al., 2010).
Based on these studies of angiogenesis in pediatric tumors, a
Phase I dose escalation study of sunitinib, a VEGF inhibitor, was
conducted in 23 children aged 2–21 with various refractory solid
tumors. Sunitinib was administered in daily 28-day cycles, with a
14-day break between cycles. The major toxicities of sunitinib in
children were neutropenia, thrombocytopenia, transaminopathy,
and fatigue. Two of 23 patients developed decreased cardiac ejec-
tion fraction. However, encouragingly, one patient with diffuse
intrinsic pontine glioma (DIPG) and one patient with a gan-
glioglioma had stable disease for 2–9 cycles. They found that
a significant correlation between treatment with sunitinib and
decreased plasma levels of endoglin, a marker of tumor-associated
endothelial cells. This result suggests that following endoglin
levels might be used in pharmacodynamic monitoring of suni-
tinib treatment in children (Dubois et al., 2011). There has also
been a study in children with recurrent high-grade gliomas in
which patients received a combination of cytotoxic chemother-
apy (mostly with irinotecan) and bevacizumab. The combination
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therapy was very well tolerated, and the greatest benefit observed
in tumors with the highest contrast enhancement (Parekh et al.,
2011). A Phase II study of sorafenib was opened for pediatric
patients with low-grade astrocytomas. This study has temporarily
been suspended, reportedly due to excess progressive disease (Clin-
ical Trials NCT01338857), but we currently await the publication
of the interim results of this trial (Karajannis, 2011).
Progression of gliomas after treatment with bevacizumab has
been reported. In fact, certain reports suggest that treatment of
high-grade gliomas with bevacizumab has precipitated a more
invasive and diffuse phenotype of gliomatosis cerebri. Treatment
with bevacizumab may also increase the rate of gliomatosis cerebri,
when compared to treatment of high-grade gliomas with conven-
tional therapies alone. However, it remains to be seen if these
trends are borne out in the data from large randomized clinical
trials and meta-analyses (Wick et al., 2011). Another retrospec-
tive study of 110 patients with high-grade gliomas treated with
bevacizumab suggests that treatment with low-dose bevacizumab
is associated with a favorable prognosis (Lorgis et al., 2012). In
children with low-grade gliomas treated with bevacizumab, dif-
fuse recurrence patterns were not seen. Patterns of progression
must be closely followed in future trials, and molecular mecha-
nisms of recurrence may further influence combination therapies
of angiogenesis inhibitors with other targeted inhibitors (Couec
et al., 2012).
In addition to bevacizumab and other targeted VEGF inhibitors
(e.g., sorafenib, sunitinib), new anti-angiogenics are also being
developed (Arbab, 2012). Thalidomide, a derivative of glutamic
acid, was initially developed as a sedative, and later was discovered
to have an immuno-modulatory role as well as anti-angiogenic
properties (Kumar and Chhibber, 2011). Thalidomide was mostly
withdrawn from clinical use secondary to its well-characterized
teratogenic effects. Later it became a mainstay of treatment in mul-
tiple myeloma, where it has shown response in more than 30% of
patients with refractory disease (Moehler, 2012). The major side
effects of thalidomide are hematologic. It causes venous throm-
boembolism and bone marrow suppression, as well as peripheral
neuropathy and secondary malignancies. The immunomodulator
functions of thalidomide and its analogs are mediated by inhibit-
ing TNF-αs. The anti-angiogenic properties of thalidomide are
mediated by down-regulating signaling from the VEGF receptor
and the FGF receptor (Shortt et al., 2013).
Early experiences with combining radiation with thalidomide
in both adult and pediatric gliomas have been discouraging.
In Radiation Therapy Oncology Group (RTOG) 9806, a single
arm Phase II study instituted by the RTOG, patients with high-
grade gliomas were treated with concurrent radiation therapy
and thalidomide (Alexander et al., 2013). There was no overall
survival benefit to this combination treatment, with a median
survival of 10 months, when compared to historical controls.
When these results are compared to the long-term results of
the randomized trial of radiotherapy versus radiotherapy and
temozolomide as published by Stupp et al. (2005) the median
survival is lower than that of the patients treated with radio-
therapy alone (12 months) and with concurrent temozolomide
and radiotherapy (14.6 months). This discrepancy in results may
be associated with the age of patients permitted to enroll (as
the Stupp study did not permit patients over 70 years of age)
or increased toxicity associated thalidomide, especially venous
thrombosis (Warren et al., 2011). Similarly, in a Phase II study
combining thalidomide and radiation therapy for pediatric brain
stem gliomas and glioblastomas, survival was not improved by the
addition of thalidomide (Turner et al., 2007). Similarly, no sur-
vival advantage has been seen in glioblastomas patients treated
adjuvantly with combinations of thalidomide with other agents
(after surgery, radiation, and temozolomide) including thalido-
mide with temozolomide; thalidomide, and temozolomide with
celecoxib (Riva et al., 2007; Kesari et al., 2008); thalidomide with
procarbazine (Ruiz et al., 2012); and thalidomide with irinotecan
(Giglio et al., 2012). However, promising early results have been
recently been reported in adult glioblastoma patients treated with
adjuvant temozolomide, thalidomide, isotretinoin with/without
celecoxib (Gilbert et al., 2010). Longer follow-up is necessary.
Children with brain tumors treated with thalidomide may fare
better. In a study by the Korean Society for Pediatric Oncology
in 12 children with DIPGs treated with radiation, followed by
temozolomide and thalidomide, the response rate was over 80%,
the 6 month progression-free survival was 58.3% and the overall
survival was 12.7 months. The regimen was well tolerated by chil-
dren with hematological toxicity being the major adverse outcome.
These results must be replicated in larger randomized studies (Kim
et al., 2010).
An analog of thalidomide, lenalidomide (CC-5013) is thought
to be more potent in its anti-inflammatory properties than
thalidomide, with a more favorable side effect profile (Shortt
et al., 2013). Its higher potency has led to several trials in which
lenalidomide is currently under investigation as an anti-cancer
agent, including multiple myeloma (Moehler, 2012), Crohn’s dis-
ease (Mansfield et al., 2007), and other solid tumors (Segler and
Tsimberidou, 2012). When lenalidomide was evaluated in adults
with recurrent primary CNS tumors in adults, as with thalido-
mide, these tumors showed no objective response to treatment
with lenalidomide but instead increased hematological toxicity
(Fine et al., 2007). However, in PBTC-018, a phase I trial of 51
pediatric patients with recurrent, refractory, or progressive CNS
tumors, objective responses were seen primarily in children with
low-grade gliomas. Lenalidomide was found to be tolerable in
children with brain tumors at doses of 116 mg/m2/day, with the
most commonly observed toxicity being myelosuppression (War-
ren et al., 2011). Lenalidomide is also being tested in combination
with radiation for pediatric DIPGs in an open National Cancer
Institute-sponsored clinical trial (NCI 10-C-0219).
SUMMARY
Multiple diverse pathways drive gliomagenesis, and their con-
vergence causes low-grade gliomas to develop, persist, and recur
after treatment. With increasing understanding of the molecular
underpinnings that drive brain tumor formation, novel targeted
strategies are being developed to combat this disease. In the treat-
ment of low-grade gliomas, which have a long natural history,
resistance to therapies is common. This review summarizes three
pathways that are the subject of current pre-clinical and clinical
studies. With the explosion of new targeted inhibitors in the can-
cer clinic, each one of these pathways can be exploited individually
or in combination with other inhibitors or radiation to develop
rational combination treatments for gliomas.
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